{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:30:39Z","timestamp":1768894239620,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Traditional Chinese Medicine Evidence-Based Capacity Building Project - Brain Diseases","award":["czbkjf20240280"],"award-info":[{"award-number":["czbkjf20240280"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      transthyretin-mediated familial amyloid polyneuropathy (ATTR-PN), caused by\n                      <jats:italic>TTR<\/jats:italic>\n                      gene mutations, leads to systemic amyloid deposition and multisystem dysfunction. The c.165G\u2009&gt;\u2009C (p.Lys55Asn) mutation is a rare variant with limited clinical data. This study investigates a family with this mutation, focusing on genotype-phenotype correlations and clinical challenges.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a detailed clinical analysis of a family with ATTR-PN, using whole exome sequencing to identify the transthyretin (\n                      <jats:italic>TTR<\/jats:italic>\n                      ) mutation. Clinical data from 17 affected individuals were collected, including symptom onset, disease progression, and outcomes. Electromyography and gastric emptying studies were performed to assess peripheral nerve and gastrointestinal function.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The c.165G\u2009&gt;\u2009C mutation was confirmed in all affected family members, presenting with early-onset gastrointestinal dysfunction and sensorimotor polyneuropathy. The mean age at onset was 39.76\u2009\u00b1\u20092.77 years, with rapid progression to death (mean age 46.13\u2009\u00b1\u20092.97 years) due to cachexia from gastrointestinal complications. Genetic anticipation was observed, with earlier onset in successive generations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The p.Lys55Asn mutation in the\n                      <jats:italic>TTR<\/jats:italic>\n                      gene leads to a severe, rapidly progressive ATTR-PN phenotype, characterized by prominent gastrointestinal dysfunction. This study enhances understanding of the clinical spectrum associated with this rare mutation, emphasizing the need for early diagnosis and targeted management strategies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04148-7","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T18:04:27Z","timestamp":1765562667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and genetic analysis of a family with transthyretin amyloid polyneuropathy caused by a TTR Lys55Asn mutation"],"prefix":"10.1186","volume":"21","author":[{"given":"Nannan","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taohua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8268-9291","authenticated-orcid":false,"given":"Wenming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaizhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"2","key":"4148_CR1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40120-021-00258-z","volume":"10","author":"M Waddington-Cruz","year":"2021","unstructured":"Waddington-Cruz M, Wixner J, Amass L, Kiszko J, Chapman D, Ando Y. Characteristics of patients with late- vs. Early-onset val30met transthyretin amyloidosis from the transthyretin amyloidosis outcomes survey (thaos). Neurol Ther. 2021;10(2):753\u201366. https:\/\/doi.org\/10.1007\/s40120-021-00258-z.","journal-title":"Neurol Ther"},{"issue":"7","key":"4148_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Reviews Neurol. 2019;15(7):387\u2013404. https:\/\/doi.org\/10.1038\/s41582-019-0210-4.","journal-title":"Nat Reviews Neurol"},{"key":"4148_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1750-1172-9-61","volume":"9","author":"J Wixner","year":"2014","unstructured":"Wixner J, Mundayat R, Karayal ON, Anan I, Karling P, Suhr OB. Thaos: Gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease. Orphanet J Rare Dis. 2014;9:61. https:\/\/doi.org\/10.1186\/1750-1172-9-61.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4148_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maurer MS, Suhr OB. Thaos - the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63\u201376. https:\/\/doi.org\/10.1185\/03007995.2012.754348.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"4148_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13023-019-1000-1","volume":"14","author":"M Waddington-Cruz","year":"2019","unstructured":"Waddington-Cruz M, Schmidt H, Botteman MF, Carter JA, Stewart M, Hopps M, et al. Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series. Orphanet J Rare Dis. 2019;14(1):34. https:\/\/doi.org\/10.1186\/s13023-019-1000-1.","journal-title":"Orphanet J Rare Dis"},{"key":"4148_CR6","doi-asserted-by":"publisher","first-page":"8677","DOI":"10.2147\/IJGM.S338430","volume":"15","author":"V V\u00e9lez-Santamar\u00eda","year":"2022","unstructured":"V\u00e9lez-Santamar\u00eda V, Nedkova-Hristova V, Morales De La Prida M, Casasnovas C. Hereditary transthyretin amyloidosis with polyneuropathy: monitoring and management. Int J Gen Med. 2022;15:8677\u201384. https:\/\/doi.org\/10.2147\/IJGM.S338430.","journal-title":"Int J Gen Med"},{"issue":"1","key":"4148_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40120-020-00180-w","volume":"9","author":"G Merlini","year":"2020","unstructured":"Merlini G, Coelho T, Waddington Cruz M, Li H, Stewart M, Ebede B. Evaluation of mortality during long-term treatment with Tafamidis for transthyretin amyloidosis with polyneuropathy: clinical trial results up to 8.5 years. Neurol Ther. 2020;9(1):105\u201315. https:\/\/doi.org\/10.1007\/s40120-020-00180-w.","journal-title":"Neurol Ther"},{"issue":"21","key":"4148_CR8","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1097\/CM9.0000000000001094","volume":"133","author":"L Liu","year":"2020","unstructured":"Liu L, Li X, Hu Z, Huang S, Tang B, Zhang R. Clinical and genetic features of transthyretin-related Familial amyloid polyneuropathy in China. Chin Med J (Engl). 2020;133(21):2616\u20138. https:\/\/doi.org\/10.1097\/CM9.0000000000001094.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"4148_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13023-020-1309-9","volume":"15","author":"A Jercan","year":"2020","unstructured":"Jercan A, Ene A, Jurcut R, Draghici M, Badelita S, Dragomir M, et al. Clinical characteristics in patients with hereditary amyloidosis with glu54gln transthyretin identified in the Romanian population. Orphanet J Rare Dis. 2020;15(1):34. https:\/\/doi.org\/10.1186\/s13023-020-1309-9.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"4148_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","volume":"9","author":"I Urits","year":"2020","unstructured":"Urits I, Swanson D, Swett MC, Patel A, Berardino K, Amgalan A, et al. A review of Patisiran (onpattro\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther. 2020;9(2):301\u201315. https:\/\/doi.org\/10.1007\/s40120-020-00208-1.","journal-title":"Neurol Ther"},{"issue":"1","key":"4148_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13023-019-1235-x","volume":"14","author":"S He","year":"2019","unstructured":"He S, Tian Z, Guan H, Li J, Fang Q, Zhang S. Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy. Orphanet J Rare Dis. 2019;14(1):251. https:\/\/doi.org\/10.1186\/s13023-019-1235-x.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"4148_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.15403\/jgld-2474","volume":"29","author":"M Luigetti","year":"2020","unstructured":"Luigetti M, Tortora A, Romano A, Di Paolantonio A, Guglielmino V, Bisogni G, et al. Gastrointestinal manifestations in hereditary transthyretin amyloidosis: a single-centre experience. J Gastrointest Liver Diseases: Jgld. 2020;29(3):339\u201343. https:\/\/doi.org\/10.15403\/jgld-2474.","journal-title":"J Gastrointest Liver Diseases: Jgld"},{"key":"4148_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/TCRM.S219979","volume":"16","author":"M Luigetti","year":"2020","unstructured":"Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and treatment of hereditary transthyretin amyloidosis (hattr) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag. 2020;16:109\u201323. https:\/\/doi.org\/10.2147\/TCRM.S219979.","journal-title":"Ther Clin Risk Manag"},{"issue":"Suppl 1","key":"4148_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10286-019-00628-6","volume":"29","author":"L Obici","year":"2019","unstructured":"Obici L, Suhr OB. Diagnosis and treatment of Gastrointestinal dysfunction in hereditary Ttr amyloidosis. Clin Auton Research: Official J Clin Auton Res Soc. 2019;29(Suppl 1):55\u201363. https:\/\/doi.org\/10.1007\/s10286-019-00628-6.","journal-title":"Clin Auton Research: Official J Clin Auton Res Soc"},{"key":"4148_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s42466-019-0035-z","volume":"1","author":"A Thimm","year":"2019","unstructured":"Thimm A, Bolz S, Fleischer M, Stolte B, Wurthmann S, Totzeck A, et al. Prevalence of hereditary transthyretin amyloid polyneuropathy in idiopathic progressive neuropathy in conurban areas. Neurol Res Pract. 2019;1:30. https:\/\/doi.org\/10.1186\/s42466-019-0035-z.","journal-title":"Neurol Res Pract"},{"issue":"5","key":"4148_CR16","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1007\/s12035-017-0593-4","volume":"55","author":"M Alves-Ferreira","year":"2018","unstructured":"Alves-Ferreira M, Coelho T, Santos D, Sequeiros J, Alonso I, Sousa A, et al. A trans-acting factor May modify age at onset in Familial amyloid polyneuropathy attrv30m in Portugal. Mol Neurobiol. 2018;55(5):3676\u201383. https:\/\/doi.org\/10.1007\/s12035-017-0593-4.","journal-title":"Mol Neurobiol"},{"key":"4148_CR17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13023-017-0710-5","volume":"12","author":"Abstracts from the","year":"2017","unstructured":"Abstracts from the. First European meeting for attr amyloidosis for Doctors and patients. Orphanet J Rare Dis. 2017;12:165.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"4148_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/jnnp-2013-305383","volume":"85","author":"C Lemos","year":"2014","unstructured":"Lemos C, Coelho T, Alves-Ferreira M, Martins-Da-Silva A, Sequeiros J, Mendon\u00e7a D, et al. Overcoming artefact: anticipation in 284 Portuguese kindreds with Familial amyloid polyneuropathy (fap) attrv30m. J Neurol Neurosurg Psychiatry. 2014;85(3):326\u201330. https:\/\/doi.org\/10.1136\/jnnp-2013-305383.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"4148_CR19","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s00415-017-8708-4","volume":"265","author":"V Plante-Bordeneuve","year":"2018","unstructured":"Plante-Bordeneuve V. Transthyretin Familial amyloid polyneuropathy: an update. J Neurol. 2018;265(4):976\u201383. https:\/\/doi.org\/10.1007\/s00415-017-8708-4.","journal-title":"J Neurol"},{"issue":"3","key":"4148_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/mus.25210","volume":"54","author":"HH Schmidt","year":"2016","unstructured":"Schmidt HH, Barroso F, Gonz\u00e1lez-Duarte A, Concei\u00e7\u00e3o I, Obici L, Keohane D, et al. Management of asymptomatic gene carriers of transthyretin Familial amyloid polyneuropathy. Muscle Nerve. 2016;54(3):353\u201360. https:\/\/doi.org\/10.1002\/mus.25210.","journal-title":"Muscle Nerve"},{"issue":"7","key":"4148_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1080\/10408363.2024.2350379","volume":"61","author":"ZL Almeida","year":"2024","unstructured":"Almeida ZL, Vaz DC, Brito RMM. Transthyretin mutagenesis: impact on amyloidogenesis and disease. Crit Rev Clin Lab Sci. 2024;61(7):616\u201340. https:\/\/doi.org\/10.1080\/10408363.2024.2350379.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"23","key":"4148_CR22","doi-asserted-by":"publisher","first-page":"13158","DOI":"10.3390\/ijms222313158","volume":"22","author":"A Gonzalez-Duarte","year":"2021","unstructured":"Gonzalez-Duarte A, Ulloa-Aguirre A. A brief journey through protein misfolding in transthyretin amyloidosis (attr amyloidosis). Int J Mol Sci. 2021;22(23):13158. https:\/\/doi.org\/10.3390\/ijms222313158.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4148_CR23","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","volume":"268","author":"D Adams","year":"2021","unstructured":"Adams D, Ando Y, Beir\u00e3o JM, Coelho T, Gertz MA, Gillmore JD, et al. Expert consensus recommendations to improve diagnosis of attr amyloidosis with polyneuropathy. J Neurol. 2021;268(6):2109\u201322. https:\/\/doi.org\/10.1007\/s00415-019-09688-0.","journal-title":"J Neurol"},{"key":"4148_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2019.05.030","volume":"403","author":"MV Pinto","year":"2019","unstructured":"Pinto MV, Pinto LF, Dias M, Rosa RS, Mundayat R, Pedrosa RC, et al. Late-onset hereditary attr v30m amyloidosis with polyneuropathy: characterization of Brazilian subjects from the Thaos registry. J Neurol Sci. 2019;403:1\u20136. https:\/\/doi.org\/10.1016\/j.jns.2019.05.030.","journal-title":"J Neurol Sci"},{"issue":"2","key":"4148_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/jns.12624","volume":"29","author":"K C\u00e1rdenas-Soto","year":"2024","unstructured":"C\u00e1rdenas-Soto K, Dominguez X, Cortes G, Tsai F, Saniger MDM, Guraieb-Chahin P, et al. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary attr amyloid polyneuropathy with Tafamidis. J Peripheral Nerv System: Jpns. 2024;29(2):221\u201331. https:\/\/doi.org\/10.1111\/jns.12624.","journal-title":"J Peripheral Nerv System: Jpns"},{"issue":"1","key":"4148_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/nmt-2018-0033","volume":"9","author":"AV Kristen","year":"2019","unstructured":"Kristen AV, Ajroud-Driss S, Concei\u00e7\u00e3o I, Gorevic P, Kyriakides T, Obici L. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener Dis Manag. 2019;9(1):5\u201323. https:\/\/doi.org\/10.2217\/nmt-2018-0033.","journal-title":"Neurodegener Dis Manag"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04148-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04148-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04148-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T18:03:22Z","timestamp":1768845802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04148-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4148"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04148-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed according to the guidelines of the Declaration of Helsinki. Written consent for publication was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"On behalf of all authors, the corresponding author states that there is no confict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}